School of Pharmacy, University of Auckland, Auckland, New Zealand.
School of Pharmacy, University of Auckland, Auckland, New Zealand.
Biol Psychiatry Cogn Neurosci Neuroimaging. 2020 Jan;5(1):45-55. doi: 10.1016/j.bpsc.2019.07.002. Epub 2019 Jul 23.
The rapid-acting clinical effects of ketamine as a novel treatment for depression along with its complex pharmacology have made it a growing research area. One of the key mechanistic hypotheses for how ketamine works to alleviate depression is by enhancing long-term potentiation (LTP)-mediated neural plasticity.
The objective of this study was to investigate the plasticity hypothesis in 30 patients with depression noninvasively using visual LTP as an index of neural plasticity. In a double-blind, active placebo-controlled crossover trial, electroencephalography-based LTP was recorded approximately 3 to 4 hours following a single 0.44-mg/kg intravenous dose of ketamine or active placebo (1.7 ng/mL remifentanil) in 30 patients. Montgomery-Åsberg Depression Rating Scale scores were used to measure clinical symptoms. Visual LTP was measured as a change in the visually evoked potential following high-frequency visual stimulation. Dynamic causal modeling investigated the underlying neural architecture of visual LTP and the contribution of ketamine.
Montgomery-Åsberg Depression Rating Scale scores revealed that 70% of participants experienced 50% or greater reduction in their depression symptoms within 1 day of receiving ketamine. LTP was demonstrated in the N1 (p = .00002) and P2 (p = 2.31 × 10) visually evoked components. Ketamine specifically enhanced P2 potentiation compared with placebo (p = .017). Dynamic causal modeling replicated the recruitment of forward and intrinsic connections for visual LTP and showed complementary effects of ketamine indicative of downstream and proplasticity modulation.
This study provides evidence that LTP-based neural plasticity increases within the time frame of the antidepressant effects of ketamine in humans and supports the hypothesis that changes to neural plasticity may be key to the antidepressant properties of ketamine.
氯胺酮作为一种新型抗抑郁治疗药物,具有快速的临床疗效,其复杂的药理学特性使其成为一个不断发展的研究领域。氯胺酮缓解抑郁的作用机制之一是增强长时程增强(LTP)介导的神经可塑性。
本研究旨在通过视觉 LTP 作为神经可塑性的指标,非侵入性地研究 30 例抑郁症患者的可塑性假说。在一项双盲、活性安慰剂对照交叉试验中,在 30 例患者中,静脉注射 0.44mg/kg 氯胺酮或活性安慰剂(1.7ng/ml 瑞芬太尼)后约 3 至 4 小时,记录基于脑电图的 LTP。使用蒙哥马利-阿斯伯格抑郁评定量表(Montgomery-Åsberg Depression Rating Scale)评分来衡量临床症状。视觉 LTP 被定义为高频视觉刺激后视觉诱发电位的变化。动态因果建模(Dynamic Causal Modeling)用于研究视觉 LTP 的潜在神经结构以及氯胺酮的作用。
蒙哥马利-阿斯伯格抑郁评定量表评分显示,70%的患者在接受氯胺酮治疗后 1 天内,其抑郁症状减轻 50%或更多。在 N1(p=0.00002)和 P2(p=2.31×10)视觉诱发电位成分中均观察到 LTP。与安慰剂相比,氯胺酮特异性增强了 P2 增强(p=0.017)。动态因果建模复制了视觉 LTP 的正向和内在连接的招募,并显示了氯胺酮的互补作用,表明下游和促进可塑性的调节。
本研究提供了证据表明,在氯胺酮抗抑郁作用的时间范围内,人类的 LTP 为基础的神经可塑性增加,并支持了神经可塑性变化可能是氯胺酮抗抑郁特性的关键假说。